2025 - ongoingTitle: CAMBRIA-2, A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective EstrogenReceptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease          Protocol Number: AZD9833-D8535C00001          Sponsor: AstraZeneca          Role: Ophthalmic assessment site

2024 - ongoingTitle: Bio Biomarker Modulation and the Inhibition of Natural Killer Type 1 (NKT1) Cells by Oral GRI-0621 in Patients with Idiopathic Pulmonary Fibrosis (IPF)          Protocol Number: GRI-0621-IPF-02          Sponsor: GRI Bio Operations, Inc          Role: Ophthalmic assessment site

2024 - ongoingTitle: ABTECT-Maintenance. A Randomised, Double-blind, Multicenter, Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis          Protocol Number: ABX464-107          Sponsor: ABIVAX          Role: Ophthalmic assessment site

2024 - ongoingTitle: ABTECT-1 Randomised, Double-blind, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of ABZ 464 Once daily for Induction Treatment in Subjects with Moderately to Severely Active Ulcerative Colitis          Protocol Number: ABX464-10          Sponsor: ABIVAX          Role: Ophthalmic assessment site

2024 - ongoingTitle: MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)          Protocal Number: ITL-2001-CL-301          Sponsor: Intellia Therapeutics          Role: Ophthalmic assessment site

2023 - 2025Title: ASPIRE: A Randomised, Double-Blind Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine with or without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma          Protocol Number: CL-SBP-101-04          Sponsor: Panbela Therapeutics          Role: Ophthalmic assessment site

2019 Title: A Clinical Effectiveness, Multicenter, Randomised, Double Controlled Study of the Efficacy and Safety of INS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Aged-related Macular Degeneration          Protocol Number: ONS-5010-002          Sponsor: GreenLight Clinical          Role: Principal Investigator

2018 - 2019 Title: Identifying microRNA and Vascular Endothelial Growth Factor (VEGF) changes in the. Blood of Age-related Macular Degeneration (AMD) patients          Grants: Canberra Health Services Private Practice Fund and Bayer Australia          Role: Principal Investigator